NEWSROOM

Press Releases
In the News
Logo & Resources Library

Recent News

Press Release
Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis
October 20, 2025
Only Treatment Option to Target Underlying Cause of Serious Lupus Complication, Aiming to Preserve Kidney Function The Lupus Research Alliance...
News Update
Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative.
Lupus Therapeutics Names Grantee for Groundbreaking IDEAL Initiative
July 24, 2025
IDEAL aims to unlock how food and gut health could improve life with lupus Imagine a future where...
News Update
Can diet make a difference in lupus?
An IDEAL Initiative in Lupus Research: Q&A With Dr. Stacie J. Bell, Lupus Therapeutics, and Dr. Teodora Staeva, Lupus Research Alliance 
March 5, 2025
Could diet and gut health impact the lived experience of lupus? This intriguing question lies at the heart of...
News Update
Breaking news: Gazyva for Lupus Nephritis
FDA Accepts Application for Potential Treatment for Lupus Nephritis, Gazyva®
March 5, 2025
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S....
News Update
Breaking News
Obinutuzumab Showed Significantly Positive Results in Published Phase III Lupus Nephritis Study
February 7, 2025
Exciting breaking news: A paper published in the highly prestigious journal New England Journal of Medicine and presented at...
News Update
A time like no other for lupus clinical research
On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP  Expresses Optimism About the Current State of Lupus Research
December 17, 2024
Today is “Endpoints Clinical Trials Day,” hosted by international biopharma news outlet Endpoints News. The day features a series...
Press Release
Request for Applications: see article for details
Lupus Therapeutics Announces a New, Groundbreaking Mechanism to Fund Clinical Studies Addressing the Impact of Diet, Nutrition, and Microbiome on Lupus
November 22, 2024
The unique IDEAL (Investigate Dietary Approaches for Lupus) Initiative will provide multidisciplinary research teams the opportunity to conduct innovative and...
News Update
LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More
November 21, 2024
New ACR guidelines for advancing the management of lupus nephritis (LN). Novel approaches and promising data from early- to...
Press Release
News from ACR Convergence 2024
Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data In Moderate-To-Severe Systemic Lupus
November 21, 2024
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3...
News Update
News from ACR Convergence 2024
ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis
November 18, 2024
The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and...
Press Release
Announcing LRA-supported research studies at ACR
Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024
November 4, 2024
Sixteen presentations of preclinical studies funded by the Lupus Research Alliance to advance understanding of lupus and potential treatment pathways,...
News Update
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
September 25, 2024
The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of...